Organisation paid for research Program year 2025 Source: CMS Open Payments

H&H Research LLC

Neither a doctor nor a teaching hospital

Research payments

$280,148

32 payments

Through program year 2025, H&H Research LLC is reported as receiving $280,148 in research payments, across 32 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$253,656	28
2024	Research	$18,492	3
2022	Research	$8,000	1

Breakdown

Who paid Research payments · program years 2022–2025

AbbVie, Inc. $280,148 32 payments

Studies the money was for Research payments · program years 2022–2025

M21-841 NOA Volume - Mid Face US Pivotal Study $112,961 16 payments
M21-841 - M21-841 NOA Volume - Mid Face US Pivotal Study $46,952 2 payments
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation $31,356 1 payment
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance $18,769 2 payments
M21-841 NOA Volume - Mid Face US Pivotal Study $17,267 2 payments
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder $15,255 5 payments
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars $12,000 1 payment
A multicenter, evaluator and subject-blinded, randomized, comparator-controlled, parallel-design study to evaluate the safety and effectiveness of NOA VOLUME compared to JUVEDERM VOLUMA XC for improvement of mid-face volume $9,167 1 payment
A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects $8,421 1 payment
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder $8,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.